SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-22-255494
Filing Date
2022-09-30
Accepted
2022-09-30 16:07:04
Documents
13
Period of Report
2022-09-27
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 1.02: Termination of a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d596886d8k.htm   iXBRL 8-K 27493
2 EX-10.1 d596886dex101.htm EX-10.1 49044
  Complete submission text file 0001193125-22-255494.txt   213354

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA sbtx-20220927.xsd EX-101.SCH 2861
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE sbtx-20220927_lab.xml EX-101.LAB 18739
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE sbtx-20220927_pre.xml EX-101.PRE 11711
7 EXTRACTED XBRL INSTANCE DOCUMENT d596886d8k_htm.xml XML 3474
Mailing Address 500 FAIRVIEW AVENUE NORTH, SUITE 600 SEATTLE WA 98109
Business Address 500 FAIRVIEW AVENUE NORTH, SUITE 600 SEATTLE WA 98109 206-456-2900
Silverback Therapeutics, Inc. (Filer) CIK: 0001671858 (see all company filings)

IRS No.: 811489190 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39756 | Film No.: 221284103
SIC: 2834 Pharmaceutical Preparations